ImmunoCAP 100TM allergen detection system is a fully automatic detection system developed and produced by Phadia Sweden (formerly Famassia Diagnostic Company) for the diagnosis of allergic diseases. Based on the patent of ImmunoCAP, the system uses fluorescence enzyme-linked immunosorbent assay to detect total IgE, specific IgE, IgG, IgA, ECP (eosinophilic cationic protein), tryptase and other items in human serum.
Product features:
1, the detection process is fully automatic, 48 tests of 4 items can be completed within 2.5 hours, and reports can be printed automatically, which greatly reduces the workload of laboratory personnel and meets the requirements of modern clinical laboratories for high efficiency.
2, the detection result is accurate, the sensitivity and specificity are high, and missed diagnosis and misdiagnosis are reduced.
3. The test results are all quantitative, and the units are in line with WHO standards. The test result is an internationally recognized quantitative unit, namely KUA/ L. ..
4. The detection method is safe and reliable, and in vitro detection avoids the potential danger of skin test, and is not affected by the patient's medication status and skin condition.
5, allergen reagent standard, containing about 600 allergens. Include univalent and multivalent allergen detection and screening test.
6. Full quantitative total IgE detection and unique ECP detection items.
7. The quality of the product is stable and reliable, and it is the first in-vitro allergen detection reagent approved by the US FDA. The production enterprise has passed the ISO quality system certification, and the product quality is stable and reliable.